This file photo shows syringes for vaccines.... The company plans to next month accelerate the pace of the trial, aiming to begin by March the final stage of study on its messenger RNA vaccine, the same type already developed by overseas companies including Pfizer Inc. and Moderna Inc.... It also was shown to inhibit mutations of the Delta variant in animal tests conducted in collaboration with the University of Tokyo, it said....

Japan, Daiichi Sankyo is the first company to develop one in this country.... Furthermore, the company

МОСКВА, 16 мая. /ТАСС/.

TOKYO: Japan's Nikkei stock average closed at a near eight-month low on Friday, dragged down by automakers and their related sectors on growing concerns about a recovery after Toyota cut its global production. The Nikkei share average fell 0.98% to close at 27, 013.25, its lowest since December 28.... The broader Topix dropped 0.87% to 1, 880.68. For the week, Nikkei shed 3.4%, the biggest weekly loss since mid-May." Toyota triggered declines in the Nikkei.... Today many other shares surroundi

TOKYO: Japan's Nikkei share average fell sharply on Thursday to hit a seven-month low following a report that Toyota Motor plans to slash its global output by 40% next month due to chip shortages. The report was the final straw for a market already struggling to shake off concerns that the fast-spreading Delta variant of COVID-19 could delay an economic recovery. The Nikkei fell 1.1% to 27, 281.17, plunging below its July trough to reach a level last seen in early January. The broader Topix lost

It provides for up to$ 2.4 billion in milestone payments, in addition to$ 200 million upfront as well as royalties if approved.It is also at least the fifth out-licensing deal potentially worth more than$ 1 billion clinched by a Chinese biotech.... The antibody also shows promise in tackling bladder and stomach tumours. Other notable deals include a Novartis AG agreement worth up to$ 2.2 billion for a BeiGene Ltd drug.... Junshi and Innovent did not respond to requests for comment. Legend was